AC
Non verificato

ACADIA Pharmaceuticals Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza
28/10/2026
Salute
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Fiere
Eventi
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
1.00
21/10/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Sanità
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
1.00
24/09/2026
Eventi
Industria
Finanza
Web e Social Network
Telefonia e Varie
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
1.00
04/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Psichiatria
Medicina - Varie
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
1.00
30/07/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
1.00
20/07/2026
Industria
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
1.00
15/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Psichiatria
Sanità
Salute
Farmaceutica
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
1.00
06/07/2026
Psichiatria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0